ALB

Executive Summary for Albemarle Investors

Shares of Industrials sector company Albemarle moved -2.5% today, and are now trading at a price of $202.89. The large-cap stock's daily volume was 2,006,354 compared to its average volume of 1,990,170. The S&P 500 index returned a -1.0% performance.

Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. The company is based in Charlotte and has 7,400 full time employees. Its market capitalization is $23,806,300,160. Albemarle currently offers its equity investors a dividend that yields 0.8% per year.

25 analysts are following Albemarle and have set target prices ranging from $155.0 to $360.0 per share. On average, they have given the company a rating of buy. At today's prices, ALB is trading -23.89% away from its average analyst target price of $266.58 per share.

Over the last year, ALB shares have gone down by -15.0%, which represents a difference of -25.0% when compared to the S&P 500. The stock's 52 week high is $334.55 per share and its 52 week low is $171.82. With average free cash flows of $1.92 Billion that have been growing at an average rate of 19.4% over the last 4 years, Albemarle declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cashflow ($ k) YoY Growth (%)
2023-02-15 1,907,849 -1,261,646 3,169,495 144.2
2022-02-22 344,257 -953,667 1,297,924 -21.31
2021-02-19 798,914 -850,477 1,649,391 5.68
2020-04-15 719,374 -841,440 1,560,814 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS